FLEXION THERAPEUTICS, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT DECEMBER 3, 2012Investor Rights Agreement • January 8th, 2014 • Flexion Therapeutics Inc • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the “Agreement”) is entered into as of the 3rd day of December, 2012, by and among FLEXION THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the investors listed on Exhibit A hereto, referred to hereinafter as the “Investors” and each individually as an “Investor.”
OUT-LICENCE AGREEMENT by and between ASTRAZENECA AB and FLEXION THERAPEUTICS INC DATE: 3RD SEPTEMBER, 2010Licence Agreement • January 8th, 2014 • Flexion Therapeutics Inc • Pharmaceutical preparations • England
NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows:
Flexion Therapeutics, Inc.Letter Agreement • January 8th, 2014 • Flexion Therapeutics Inc • Pharmaceutical preparations • Massachusetts
This letter agreement (the “Agreement”) sets forth the terms of your continued employment as Chief Medical Officer (“CMO”) of Flexion Therapeutics, Inc. (the “Company”). This Agreement will become effective upon your acceptance by executing this Agreement and returning the executed Agreement to me. As of its effective date this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated November 15, 2007 (the “Prior Agreement”) except that the terms of your Proprietary Information and Inventions Agreement executed on January 7, 2010 shall continue to apply.
August 28, 2013 Mr. Arthur J. Fratamico Dear Art:Letter Agreement • January 8th, 2014 • Flexion Therapeutics Inc • Pharmaceutical preparations
This letter agreement (the “Agreement”) sets forth the terms of your continued employment with Flexion Therapeutics, Inc. (the “Company”), in the full time position of Chief Business Officer, reporting to Michael Clayman, Chief Executive Officer. This Agreement will become effective upon your execution below. As of its effective date this Agreement will replace and supersede in its entirety the letter agreement between you and the Company dated May 10, 2012 (the “Prior Agreement”), except that the terms of your Proprietary Information, Inventions, Non-Solicitation, and Non-Competition Agreement executed on May 27, 2012 shall continue to apply.
BURLINGTON, MASSACHUSETTS Lease Dated February 22, 2013Burlington Mall Road • January 8th, 2014 • Flexion Therapeutics Inc • Pharmaceutical preparations • Massachusetts
THIS INSTRUMENT IS AN INDENTURE OF LEASE in which the Landlord and the Tenant are the parties hereinafter named, and which relates to space in a certain building (the “Building”) known as, and with an address at, 10 Burlington Mall Road, Burlington, Massachusetts 01803.
December 3, 2012 AstraZeneca AB SE-431 83 Mölndal Sweden Re: Out-License Agreement by and between AstraZeneca AB (“AstraZeneca”) and Flexion Therapeutics AG (“Flexion”) effective June 12, 2009 (the “Agreement”) Dear Sirs,Flexion Therapeutics Inc • January 8th, 2014 • Pharmaceutical preparations
This letter sets forth our mutual understanding and certain amendments to the Agreement with respect to Licensed Products and Compounds (the compound known as FX005 ([…***…])). Capitalized terms used herein and not otherwise defined shall be given the meaning in the Agreement. In consideration of the rights and covenants of the Parties the sufficiency of which is acknowledged, Flexion and AstraZeneca agree as follows:
